Lilly strengthens Zyprexa warnings

Eli Lilly is owning up to Zyprexa's ills in new warnings added to the medicine's label. The schizophrenia drug will now be tagged with weight gain, high blood sugar high cholesterol, and other metabolic problems.

It's the first time Zyprexa's label has acknowledged that it causes high blood sugar more readily than other atypical antipsychotics. In fact, Lilly has argued against it, saying that the difference wasn't proven. The label also admits that weight gain may continue for as long as two years, rather than plateauing in a few months as previously stated.

Though Zyprexa has steadily lost market share since 2004 because of side effects, it still delivered $2.3 billion in worldwide sales the first half of this year.

- see Lilly's release
- read the article from the New York Times

Related Articles:
Lilly CEO: Use IT to boost drug safety. Report
Eli Lilly pairs with GE to study cancer drugs. Report
Lilly developing biotech drugs the old-fashioned way. Report
Lilly accused of promoting off-label Zyprexa use. Report
NYT accuses Lilly of hiding safety problems. Report

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.